nodes	percent_of_prediction	percent_of_DWPC	metapath
Ruxolitinib—Protein Kinase Inhibitors—Temsirolimus—kidney cancer	0.161	0.344	CiPCiCtD
Ruxolitinib—LRRK2—kidney cancer	0.134	1	CbGaD
Ruxolitinib—Protein Kinase Inhibitors—Sunitinib—kidney cancer	0.122	0.261	CiPCiCtD
Ruxolitinib—Protein Kinase Inhibitors—Everolimus—kidney cancer	0.0926	0.198	CiPCiCtD
Ruxolitinib—Protein Kinase Inhibitors—Pazopanib—kidney cancer	0.0926	0.198	CiPCiCtD
Ruxolitinib—STK16—Pazopanib—kidney cancer	0.0148	0.0511	CbGbCtD
Ruxolitinib—JAK3—Erlotinib—kidney cancer	0.0106	0.0365	CbGbCtD
Ruxolitinib—TAOK3—Pazopanib—kidney cancer	0.00985	0.034	CbGbCtD
Ruxolitinib—PLK4—Pazopanib—kidney cancer	0.00985	0.034	CbGbCtD
Ruxolitinib—MARK2—Sunitinib—kidney cancer	0.00963	0.0333	CbGbCtD
Ruxolitinib—DAPK2—Sunitinib—kidney cancer	0.00963	0.0333	CbGbCtD
Ruxolitinib—GRK7—Sunitinib—kidney cancer	0.00963	0.0333	CbGbCtD
Ruxolitinib—HIPK2—Sunitinib—kidney cancer	0.00963	0.0333	CbGbCtD
Ruxolitinib—CLK2—Sunitinib—kidney cancer	0.00963	0.0333	CbGbCtD
Ruxolitinib—DCLK3—Sunitinib—kidney cancer	0.00963	0.0333	CbGbCtD
Ruxolitinib—DAPK3—Sunitinib—kidney cancer	0.00963	0.0333	CbGbCtD
Ruxolitinib—GRK1—Sunitinib—kidney cancer	0.00963	0.0333	CbGbCtD
Ruxolitinib—TAOK2—Sorafenib—kidney cancer	0.0086	0.0297	CbGbCtD
Ruxolitinib—MKNK2—Sorafenib—kidney cancer	0.0086	0.0297	CbGbCtD
Ruxolitinib—MAP3K2—Pazopanib—kidney cancer	0.00851	0.0294	CbGbCtD
Ruxolitinib—LTK—Erlotinib—kidney cancer	0.0084	0.029	CbGbCtD
Ruxolitinib—DYRK1A—Sunitinib—kidney cancer	0.00697	0.024	CbGbCtD
Ruxolitinib—PHKG2—Sunitinib—kidney cancer	0.00697	0.024	CbGbCtD
Ruxolitinib—TYK2—Sunitinib—kidney cancer	0.00697	0.024	CbGbCtD
Ruxolitinib—CAMK2G—Sunitinib—kidney cancer	0.00697	0.024	CbGbCtD
Ruxolitinib—LRRK2—Sunitinib—kidney cancer	0.00697	0.024	CbGbCtD
Ruxolitinib—ROCK1—Sunitinib—kidney cancer	0.00697	0.024	CbGbCtD
Ruxolitinib—STK16—Sunitinib—kidney cancer	0.00697	0.024	CbGbCtD
Ruxolitinib—MAST1—Sunitinib—kidney cancer	0.00697	0.024	CbGbCtD
Ruxolitinib—MAP3K7—Sorafenib—kidney cancer	0.00683	0.0236	CbGbCtD
Ruxolitinib—MAP3K19—Pazopanib—kidney cancer	0.00566	0.0195	CbGbCtD
Ruxolitinib—MAP3K7—Sunitinib—kidney cancer	0.00553	0.0191	CbGbCtD
Ruxolitinib—JAK2—Sunitinib—kidney cancer	0.00553	0.0191	CbGbCtD
Ruxolitinib—BMP2K—Sunitinib—kidney cancer	0.00553	0.0191	CbGbCtD
Ruxolitinib—NUAK2—Sunitinib—kidney cancer	0.00553	0.0191	CbGbCtD
Ruxolitinib—RET—Sorafenib—kidney cancer	0.00494	0.017	CbGbCtD
Ruxolitinib—MAP3K3—Sunitinib—kidney cancer	0.00463	0.016	CbGbCtD
Ruxolitinib—PLK4—Sunitinib—kidney cancer	0.00463	0.016	CbGbCtD
Ruxolitinib—TAOK3—Sunitinib—kidney cancer	0.00463	0.016	CbGbCtD
Ruxolitinib—MAP3K19—Erlotinib—kidney cancer	0.00404	0.0139	CbGbCtD
Ruxolitinib—MAP3K2—Sunitinib—kidney cancer	0.004	0.0138	CbGbCtD
Ruxolitinib—RET—Sunitinib—kidney cancer	0.004	0.0138	CbGbCtD
Ruxolitinib—IRAK1—Sunitinib—kidney cancer	0.004	0.0138	CbGbCtD
Ruxolitinib—MAP3K19—Sorafenib—kidney cancer	0.00328	0.0113	CbGbCtD
Ruxolitinib—MAP3K19—Sunitinib—kidney cancer	0.00266	0.00918	CbGbCtD
Ruxolitinib—DCLK3—urine—kidney cancer	0.00204	0.0888	CbGeAlD
Ruxolitinib—CYP3A4—Everolimus—kidney cancer	0.00068	0.00235	CbGbCtD
Ruxolitinib—PRKG2—renal system—kidney cancer	0.000587	0.0256	CbGeAlD
Ruxolitinib—PRKG2—kidney—kidney cancer	0.000567	0.0247	CbGeAlD
Ruxolitinib—PLK1—gonad—kidney cancer	0.000472	0.0206	CbGeAlD
Ruxolitinib—CYP3A4—Temsirolimus—kidney cancer	0.000459	0.00158	CbGbCtD
Ruxolitinib—PLK3—cardiac atrium—kidney cancer	0.000393	0.0171	CbGeAlD
Ruxolitinib—CAMK1—cortex of kidney—kidney cancer	0.000387	0.0168	CbGeAlD
Ruxolitinib—JAK1—nephron tubule—kidney cancer	0.000371	0.0161	CbGeAlD
Ruxolitinib—CAMK1—gonad—kidney cancer	0.000368	0.016	CbGeAlD
Ruxolitinib—HIPK2—nephron tubule—kidney cancer	0.000346	0.0151	CbGeAlD
Ruxolitinib—JAK1—renal system—kidney cancer	0.000337	0.0147	CbGeAlD
Ruxolitinib—JAK1—kidney—kidney cancer	0.000326	0.0142	CbGeAlD
Ruxolitinib—JAK1—cortex of kidney—kidney cancer	0.000317	0.0138	CbGeAlD
Ruxolitinib—HIPK2—renal system—kidney cancer	0.000315	0.0137	CbGeAlD
Ruxolitinib—HIPK2—kidney—kidney cancer	0.000304	0.0132	CbGeAlD
Ruxolitinib—DAPK2—cortex of kidney—kidney cancer	0.000303	0.0132	CbGeAlD
Ruxolitinib—DAPK3—renal system—kidney cancer	0.000302	0.0132	CbGeAlD
Ruxolitinib—JAK1—gonad—kidney cancer	0.000302	0.0132	CbGeAlD
Ruxolitinib—JAK1—cardiac atrium—kidney cancer	0.000302	0.0131	CbGeAlD
Ruxolitinib—PLK4—gonad—kidney cancer	0.0003	0.0131	CbGeAlD
Ruxolitinib—CLK2—renal system—kidney cancer	0.000299	0.013	CbGeAlD
Ruxolitinib—NUAK2—nephron tubule—kidney cancer	0.000296	0.0129	CbGeAlD
Ruxolitinib—HIPK2—cortex of kidney—kidney cancer	0.000296	0.0129	CbGeAlD
Ruxolitinib—CAMK1D—cardiac atrium—kidney cancer	0.000294	0.0128	CbGeAlD
Ruxolitinib—PHKG2—gonad—kidney cancer	0.000293	0.0128	CbGeAlD
Ruxolitinib—ROCK1—renal system—kidney cancer	0.00029	0.0126	CbGeAlD
Ruxolitinib—DAPK2—cardiac atrium—kidney cancer	0.000288	0.0125	CbGeAlD
Ruxolitinib—DYRK1A—renal system—kidney cancer	0.000283	0.0123	CbGeAlD
Ruxolitinib—HIPK2—gonad—kidney cancer	0.000282	0.0123	CbGeAlD
Ruxolitinib—CLK2—cortex of kidney—kidney cancer	0.000282	0.0123	CbGeAlD
Ruxolitinib—BMPR2—renal system—kidney cancer	0.000282	0.0123	CbGeAlD
Ruxolitinib—ROCK1—kidney—kidney cancer	0.00028	0.0122	CbGeAlD
Ruxolitinib—DYRK1A—kidney—kidney cancer	0.000274	0.0119	CbGeAlD
Ruxolitinib—BMPR2—kidney—kidney cancer	0.000272	0.0119	CbGeAlD
Ruxolitinib—DAPK3—cardiac atrium—kidney cancer	0.000271	0.0118	CbGeAlD
Ruxolitinib—PLK1—Tacrolimus—Everolimus—kidney cancer	0.000269	0.228	CbGdCrCtD
Ruxolitinib—PLK1—Tacrolimus—Temsirolimus—kidney cancer	0.000269	0.228	CbGdCrCtD
Ruxolitinib—CLK2—gonad—kidney cancer	0.000268	0.0117	CbGeAlD
Ruxolitinib—CLK2—cardiac atrium—kidney cancer	0.000268	0.0117	CbGeAlD
Ruxolitinib—BMPR2—cortex of kidney—kidney cancer	0.000265	0.0116	CbGeAlD
Ruxolitinib—ROCK1—gonad—kidney cancer	0.00026	0.0113	CbGeAlD
Ruxolitinib—DYRK1A—gonad—kidney cancer	0.000254	0.0111	CbGeAlD
Ruxolitinib—NUAK2—cortex of kidney—kidney cancer	0.000254	0.011	CbGeAlD
Ruxolitinib—BMPR2—cardiac atrium—kidney cancer	0.000252	0.011	CbGeAlD
Ruxolitinib—MAP3K2—nephron tubule—kidney cancer	0.000252	0.011	CbGeAlD
Ruxolitinib—LRRK2—renal system—kidney cancer	0.00025	0.0109	CbGeAlD
Ruxolitinib—TYK2—nephron tubule—kidney cancer	0.000245	0.0107	CbGeAlD
Ruxolitinib—IRAK1—nephron tubule—kidney cancer	0.000242	0.0105	CbGeAlD
Ruxolitinib—MKNK2—nephron tubule—kidney cancer	0.000242	0.0105	CbGeAlD
Ruxolitinib—LRRK2—kidney—kidney cancer	0.000242	0.0105	CbGeAlD
Ruxolitinib—CYP3A4—Pazopanib—kidney cancer	0.000241	0.000833	CbGbCtD
Ruxolitinib—CAMK2G—cortex of kidney—kidney cancer	0.000237	0.0103	CbGeAlD
Ruxolitinib—LRRK2—cortex of kidney—kidney cancer	0.000235	0.0103	CbGeAlD
Ruxolitinib—BMP2K—gonad—kidney cancer	0.000226	0.00985	CbGeAlD
Ruxolitinib—LRRK2—gonad—kidney cancer	0.000224	0.00976	CbGeAlD
Ruxolitinib—TYK2—renal system—kidney cancer	0.000223	0.0097	CbGeAlD
Ruxolitinib—CYP3A4—urine—kidney cancer	0.000221	0.00963	CbGeAlD
Ruxolitinib—MKNK2—renal system—kidney cancer	0.00022	0.00958	CbGeAlD
Ruxolitinib—TYK2—kidney—kidney cancer	0.000215	0.00938	CbGeAlD
Ruxolitinib—MAP3K3—nephron tubule—kidney cancer	0.000215	0.00936	CbGeAlD
Ruxolitinib—RET—renal system—kidney cancer	0.000214	0.00934	CbGeAlD
Ruxolitinib—MAP3K7—cortex of kidney—kidney cancer	0.000214	0.0093	CbGeAlD
Ruxolitinib—TYK2—cortex of kidney—kidney cancer	0.00021	0.00914	CbGeAlD
Ruxolitinib—RET—kidney—kidney cancer	0.000207	0.00903	CbGeAlD
Ruxolitinib—MKNK2—cortex of kidney—kidney cancer	0.000207	0.00902	CbGeAlD
Ruxolitinib—IRAK1—cortex of kidney—kidney cancer	0.000207	0.00902	CbGeAlD
Ruxolitinib—MAP3K2—gonad—kidney cancer	0.000205	0.00895	CbGeAlD
Ruxolitinib—MAP3K7—cardiac atrium—kidney cancer	0.000203	0.00885	CbGeAlD
Ruxolitinib—JAK2—renal system—kidney cancer	0.000203	0.00883	CbGeAlD
Ruxolitinib—TYK2—cardiac atrium—kidney cancer	0.0002	0.00869	CbGeAlD
Ruxolitinib—MKNK2—gonad—kidney cancer	0.000197	0.00859	CbGeAlD
Ruxolitinib—MKNK2—cardiac atrium—kidney cancer	0.000197	0.00858	CbGeAlD
Ruxolitinib—JAK2—kidney—kidney cancer	0.000196	0.00853	CbGeAlD
Ruxolitinib—TAOK3—nephron tubule—kidney cancer	0.000196	0.00853	CbGeAlD
Ruxolitinib—JAK2—cortex of kidney—kidney cancer	0.000191	0.00831	CbGeAlD
Ruxolitinib—MAP3K3—cortex of kidney—kidney cancer	0.000184	0.00801	CbGeAlD
Ruxolitinib—JAK2—gonad—kidney cancer	0.000182	0.00792	CbGeAlD
Ruxolitinib—JAK2—cardiac atrium—kidney cancer	0.000182	0.00791	CbGeAlD
Ruxolitinib—TAOK3—renal system—kidney cancer	0.000178	0.00776	CbGeAlD
Ruxolitinib—MAP3K3—gonad—kidney cancer	0.000175	0.00763	CbGeAlD
Ruxolitinib—MAP3K3—cardiac atrium—kidney cancer	0.000175	0.00762	CbGeAlD
Ruxolitinib—TAOK3—kidney—kidney cancer	0.000172	0.0075	CbGeAlD
Ruxolitinib—CYP3A4—Erlotinib—kidney cancer	0.000172	0.000594	CbGbCtD
Ruxolitinib—TAOK3—cortex of kidney—kidney cancer	0.000168	0.0073	CbGeAlD
Ruxolitinib—TAOK3—cardiac atrium—kidney cancer	0.000159	0.00695	CbGeAlD
Ruxolitinib—CYP3A4—Paclitaxel—kidney cancer	0.000158	0.000544	CbGbCtD
Ruxolitinib—CYP3A4—Sorafenib—kidney cancer	0.00014	0.000483	CbGbCtD
Ruxolitinib—CYP3A4—Vinblastine—kidney cancer	0.000138	0.000477	CbGbCtD
Ruxolitinib—CYP3A4—Vincristine—kidney cancer	0.000136	0.000469	CbGbCtD
Ruxolitinib—Anaemia—Temsirolimus—kidney cancer	0.000127	0.00385	CcSEcCtD
Ruxolitinib—Infestation—Erlotinib—kidney cancer	0.000127	0.00382	CcSEcCtD
Ruxolitinib—Infestation NOS—Erlotinib—kidney cancer	0.000127	0.00382	CcSEcCtD
Ruxolitinib—Alanine aminotransferase increased—Sunitinib—kidney cancer	0.000125	0.00379	CcSEcCtD
Ruxolitinib—Haematuria—Everolimus—kidney cancer	0.000125	0.00378	CcSEcCtD
Ruxolitinib—Hepatobiliary disease—Everolimus—kidney cancer	0.000124	0.00375	CcSEcCtD
Ruxolitinib—Contusion—Capecitabine—kidney cancer	0.000124	0.00374	CcSEcCtD
Ruxolitinib—Epistaxis—Everolimus—kidney cancer	0.000124	0.00374	CcSEcCtD
Ruxolitinib—Anaemia—Pazopanib—kidney cancer	0.00012	0.00362	CcSEcCtD
Ruxolitinib—Hepatobiliary disease—Erlotinib—kidney cancer	0.00012	0.00361	CcSEcCtD
Ruxolitinib—Neutropenia—Sorafenib—kidney cancer	0.000119	0.0036	CcSEcCtD
Ruxolitinib—Epistaxis—Erlotinib—kidney cancer	0.000119	0.0036	CcSEcCtD
Ruxolitinib—Haemoglobin—Vinblastine—kidney cancer	0.000119	0.00359	CcSEcCtD
Ruxolitinib—Haemoglobin—Everolimus—kidney cancer	0.000118	0.00357	CcSEcCtD
Ruxolitinib—Haemorrhage—Vinblastine—kidney cancer	0.000118	0.00357	CcSEcCtD
Ruxolitinib—Haemorrhage—Everolimus—kidney cancer	0.000118	0.00355	CcSEcCtD
Ruxolitinib—Pancytopenia—Sunitinib—kidney cancer	0.000117	0.00352	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Temsirolimus—kidney cancer	0.000116	0.00352	CcSEcCtD
Ruxolitinib—Weight decreased—Sorafenib—kidney cancer	0.000116	0.00349	CcSEcCtD
Ruxolitinib—Neutropenia—Sunitinib—kidney cancer	0.000115	0.00347	CcSEcCtD
Ruxolitinib—Haemoglobin—Erlotinib—kidney cancer	0.000114	0.00345	CcSEcCtD
Ruxolitinib—Infestation—Sorafenib—kidney cancer	0.000114	0.00344	CcSEcCtD
Ruxolitinib—Infestation NOS—Sorafenib—kidney cancer	0.000114	0.00344	CcSEcCtD
Ruxolitinib—Haemorrhage—Erlotinib—kidney cancer	0.000114	0.00343	CcSEcCtD
Ruxolitinib—CYP3A4—Sunitinib—kidney cancer	0.000113	0.000391	CbGbCtD
Ruxolitinib—Bone pain—Capecitabine—kidney cancer	0.000113	0.0034	CcSEcCtD
Ruxolitinib—Infection—Temsirolimus—kidney cancer	0.000112	0.00337	CcSEcCtD
Ruxolitinib—Weight decreased—Sunitinib—kidney cancer	0.000111	0.00336	CcSEcCtD
Ruxolitinib—Pancytopenia—Dactinomycin—kidney cancer	0.00011	0.00334	CcSEcCtD
Ruxolitinib—Nervous system disorder—Temsirolimus—kidney cancer	0.00011	0.00333	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Temsirolimus—kidney cancer	0.00011	0.00332	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Pazopanib—kidney cancer	0.00011	0.00331	CcSEcCtD
Ruxolitinib—Infestation—Sunitinib—kidney cancer	0.00011	0.00331	CcSEcCtD
Ruxolitinib—Infestation NOS—Sunitinib—kidney cancer	0.00011	0.00331	CcSEcCtD
Ruxolitinib—Skin disorder—Temsirolimus—kidney cancer	0.000109	0.0033	CcSEcCtD
Ruxolitinib—Neutropenia—Dactinomycin—kidney cancer	0.000109	0.00328	CcSEcCtD
Ruxolitinib—Hepatobiliary disease—Sorafenib—kidney cancer	0.000108	0.00325	CcSEcCtD
Ruxolitinib—Epistaxis—Sorafenib—kidney cancer	0.000107	0.00324	CcSEcCtD
Ruxolitinib—Urinary tract infection—Sunitinib—kidney cancer	0.000106	0.00322	CcSEcCtD
Ruxolitinib—Infection—Pazopanib—kidney cancer	0.000105	0.00318	CcSEcCtD
Ruxolitinib—Nervous system disorder—Pazopanib—kidney cancer	0.000104	0.00314	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Pazopanib—kidney cancer	0.000104	0.00313	CcSEcCtD
Ruxolitinib—Hepatobiliary disease—Sunitinib—kidney cancer	0.000104	0.00313	CcSEcCtD
Ruxolitinib—Epistaxis—Sunitinib—kidney cancer	0.000103	0.00312	CcSEcCtD
Ruxolitinib—Skin disorder—Pazopanib—kidney cancer	0.000103	0.00311	CcSEcCtD
Ruxolitinib—Haemoglobin—Sorafenib—kidney cancer	0.000103	0.0031	CcSEcCtD
Ruxolitinib—Malnutrition—Everolimus—kidney cancer	0.000102	0.00309	CcSEcCtD
Ruxolitinib—Haemorrhage—Sorafenib—kidney cancer	0.000102	0.00309	CcSEcCtD
Ruxolitinib—Flatulence—Everolimus—kidney cancer	0.000101	0.00305	CcSEcCtD
Ruxolitinib—Alanine aminotransferase increased—Gemcitabine—kidney cancer	0.000101	0.00304	CcSEcCtD
Ruxolitinib—Malnutrition—Erlotinib—kidney cancer	9.89e-05	0.00299	CcSEcCtD
Ruxolitinib—Haemoglobin—Sunitinib—kidney cancer	9.88e-05	0.00298	CcSEcCtD
Ruxolitinib—Pancytopenia—Vincristine—kidney cancer	9.87e-05	0.00298	CcSEcCtD
Ruxolitinib—Haemorrhage—Sunitinib—kidney cancer	9.83e-05	0.00297	CcSEcCtD
Ruxolitinib—Flatulence—Erlotinib—kidney cancer	9.74e-05	0.00294	CcSEcCtD
Ruxolitinib—Neutropenia—Vincristine—kidney cancer	9.72e-05	0.00293	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Temsirolimus—kidney cancer	9.71e-05	0.00293	CcSEcCtD
Ruxolitinib—Fatigue—Temsirolimus—kidney cancer	9.7e-05	0.00293	CcSEcCtD
Ruxolitinib—Anaemia—Vinblastine—kidney cancer	9.51e-05	0.00287	CcSEcCtD
Ruxolitinib—Anaemia—Everolimus—kidney cancer	9.47e-05	0.00286	CcSEcCtD
Ruxolitinib—Weight decreased—Vincristine—kidney cancer	9.4e-05	0.00284	CcSEcCtD
Ruxolitinib—Pancytopenia—Gemcitabine—kidney cancer	9.36e-05	0.00283	CcSEcCtD
Ruxolitinib—Herpes zoster—Doxorubicin—kidney cancer	9.24e-05	0.00279	CcSEcCtD
Ruxolitinib—Neutropenia—Gemcitabine—kidney cancer	9.22e-05	0.00278	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Pazopanib—kidney cancer	9.15e-05	0.00276	CcSEcCtD
Ruxolitinib—Fatigue—Pazopanib—kidney cancer	9.13e-05	0.00276	CcSEcCtD
Ruxolitinib—Malnutrition—Sorafenib—kidney cancer	8.9e-05	0.00269	CcSEcCtD
Ruxolitinib—Body temperature increased—Temsirolimus—kidney cancer	8.89e-05	0.00268	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Everolimus—kidney cancer	8.67e-05	0.00262	CcSEcCtD
Ruxolitinib—Malnutrition—Sunitinib—kidney cancer	8.56e-05	0.00258	CcSEcCtD
Ruxolitinib—CYP3A4—Doxorubicin—kidney cancer	8.49e-05	0.000293	CbGbCtD
Ruxolitinib—Flatulence—Sunitinib—kidney cancer	8.44e-05	0.00255	CcSEcCtD
Ruxolitinib—Alanine aminotransferase increased—Paclitaxel—kidney cancer	8.42e-05	0.00254	CcSEcCtD
Ruxolitinib—Haematuria—Gemcitabine—kidney cancer	8.38e-05	0.00253	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Erlotinib—kidney cancer	8.36e-05	0.00252	CcSEcCtD
Ruxolitinib—Hepatobiliary disease—Gemcitabine—kidney cancer	8.31e-05	0.00251	CcSEcCtD
Ruxolitinib—Infection—Everolimus—kidney cancer	8.31e-05	0.00251	CcSEcCtD
Ruxolitinib—Anaemia—Sorafenib—kidney cancer	8.22e-05	0.00248	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Vinblastine—kidney cancer	8.22e-05	0.00248	CcSEcCtD
Ruxolitinib—Nervous system disorder—Everolimus—kidney cancer	8.2e-05	0.00248	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Everolimus—kidney cancer	8.19e-05	0.00247	CcSEcCtD
Ruxolitinib—Skin disorder—Everolimus—kidney cancer	8.12e-05	0.00245	CcSEcCtD
Ruxolitinib—Asthenia—Temsirolimus—kidney cancer	8.07e-05	0.00244	CcSEcCtD
Ruxolitinib—Infection—Erlotinib—kidney cancer	8.02e-05	0.00242	CcSEcCtD
Ruxolitinib—Pruritus—Temsirolimus—kidney cancer	7.96e-05	0.0024	CcSEcCtD
Ruxolitinib—Haemoglobin—Gemcitabine—kidney cancer	7.93e-05	0.00239	CcSEcCtD
Ruxolitinib—Nervous system disorder—Erlotinib—kidney cancer	7.92e-05	0.00239	CcSEcCtD
Ruxolitinib—Anaemia—Sunitinib—kidney cancer	7.91e-05	0.00239	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Erlotinib—kidney cancer	7.9e-05	0.00239	CcSEcCtD
Ruxolitinib—Haemorrhage—Gemcitabine—kidney cancer	7.89e-05	0.00238	CcSEcCtD
Ruxolitinib—Skin disorder—Erlotinib—kidney cancer	7.84e-05	0.00237	CcSEcCtD
Ruxolitinib—Pancytopenia—Paclitaxel—kidney cancer	7.84e-05	0.00237	CcSEcCtD
Ruxolitinib—Gastrointestinal haemorrhage—Capecitabine—kidney cancer	7.84e-05	0.00237	CcSEcCtD
Ruxolitinib—Neutropenia—Paclitaxel—kidney cancer	7.72e-05	0.00233	CcSEcCtD
Ruxolitinib—PLK1—Temsirolimus—Everolimus—kidney cancer	7.7e-05	0.0653	CbGdCrCtD
Ruxolitinib—PLK1—Sirolimus—Everolimus—kidney cancer	7.7e-05	0.0653	CbGdCrCtD
Ruxolitinib—PLK1—Everolimus—Temsirolimus—kidney cancer	7.7e-05	0.0653	CbGdCrCtD
Ruxolitinib—PLK1—Sirolimus—Temsirolimus—kidney cancer	7.7e-05	0.0653	CbGdCrCtD
Ruxolitinib—Asthenia—Pazopanib—kidney cancer	7.6e-05	0.00229	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—kidney cancer	7.52e-05	0.00227	CcSEcCtD
Ruxolitinib—Weight increased—Paclitaxel—kidney cancer	7.51e-05	0.00227	CcSEcCtD
Ruxolitinib—Pruritus—Pazopanib—kidney cancer	7.5e-05	0.00226	CcSEcCtD
Ruxolitinib—Anaemia—Dactinomycin—kidney cancer	7.49e-05	0.00226	CcSEcCtD
Ruxolitinib—Weight decreased—Paclitaxel—kidney cancer	7.47e-05	0.00225	CcSEcCtD
Ruxolitinib—Dizziness—Temsirolimus—kidney cancer	7.44e-05	0.00225	CcSEcCtD
Ruxolitinib—Infestation—Paclitaxel—kidney cancer	7.36e-05	0.00222	CcSEcCtD
Ruxolitinib—Infestation NOS—Paclitaxel—kidney cancer	7.36e-05	0.00222	CcSEcCtD
Ruxolitinib—CAMK2G—Azacitidine—Gemcitabine—kidney cancer	7.3e-05	0.0619	CbGdCrCtD
Ruxolitinib—Bone pain—Doxorubicin—kidney cancer	7.26e-05	0.00219	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Sunitinib—kidney cancer	7.24e-05	0.00219	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Everolimus—kidney cancer	7.22e-05	0.00218	CcSEcCtD
Ruxolitinib—Infection—Sorafenib—kidney cancer	7.21e-05	0.00218	CcSEcCtD
Ruxolitinib—Fatigue—Everolimus—kidney cancer	7.21e-05	0.00218	CcSEcCtD
Ruxolitinib—Urinary tract infection—Paclitaxel—kidney cancer	7.15e-05	0.00216	CcSEcCtD
Ruxolitinib—Nervous system disorder—Sorafenib—kidney cancer	7.12e-05	0.00215	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Sorafenib—kidney cancer	7.11e-05	0.00215	CcSEcCtD
Ruxolitinib—Skin disorder—Sorafenib—kidney cancer	7.05e-05	0.00213	CcSEcCtD
Ruxolitinib—Headache—Temsirolimus—kidney cancer	7.04e-05	0.00213	CcSEcCtD
Ruxolitinib—Haematuria—Paclitaxel—kidney cancer	7.02e-05	0.00212	CcSEcCtD
Ruxolitinib—Dizziness—Pazopanib—kidney cancer	7.01e-05	0.00212	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Erlotinib—kidney cancer	6.97e-05	0.0021	CcSEcCtD
Ruxolitinib—Hepatobiliary disease—Paclitaxel—kidney cancer	6.96e-05	0.0021	CcSEcCtD
Ruxolitinib—Fatigue—Erlotinib—kidney cancer	6.96e-05	0.0021	CcSEcCtD
Ruxolitinib—Epistaxis—Paclitaxel—kidney cancer	6.94e-05	0.0021	CcSEcCtD
Ruxolitinib—Infection—Sunitinib—kidney cancer	6.94e-05	0.0021	CcSEcCtD
Ruxolitinib—Alanine aminotransferase increased—Capecitabine—kidney cancer	6.91e-05	0.00209	CcSEcCtD
Ruxolitinib—Nervous system disorder—Sunitinib—kidney cancer	6.85e-05	0.00207	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Sunitinib—kidney cancer	6.84e-05	0.00207	CcSEcCtD
Ruxolitinib—Skin disorder—Sunitinib—kidney cancer	6.79e-05	0.00205	CcSEcCtD
Ruxolitinib—Anaemia—Vincristine—kidney cancer	6.69e-05	0.00202	CcSEcCtD
Ruxolitinib—Haemoglobin—Paclitaxel—kidney cancer	6.64e-05	0.002	CcSEcCtD
Ruxolitinib—Headache—Pazopanib—kidney cancer	6.64e-05	0.002	CcSEcCtD
Ruxolitinib—Body temperature increased—Everolimus—kidney cancer	6.61e-05	0.002	CcSEcCtD
Ruxolitinib—Haemorrhage—Paclitaxel—kidney cancer	6.61e-05	0.00199	CcSEcCtD
Ruxolitinib—Infection—Dactinomycin—kidney cancer	6.57e-05	0.00198	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Dactinomycin—kidney cancer	6.48e-05	0.00196	CcSEcCtD
Ruxolitinib—Pancytopenia—Capecitabine—kidney cancer	6.43e-05	0.00194	CcSEcCtD
Ruxolitinib—Body temperature increased—Erlotinib—kidney cancer	6.38e-05	0.00193	CcSEcCtD
Ruxolitinib—Anaemia—Gemcitabine—kidney cancer	6.35e-05	0.00192	CcSEcCtD
Ruxolitinib—Neutropenia—Capecitabine—kidney cancer	6.33e-05	0.00191	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Sorafenib—kidney cancer	6.27e-05	0.00189	CcSEcCtD
Ruxolitinib—Fatigue—Sorafenib—kidney cancer	6.26e-05	0.00189	CcSEcCtD
Ruxolitinib—Weight increased—Capecitabine—kidney cancer	6.16e-05	0.00186	CcSEcCtD
Ruxolitinib—Weight decreased—Capecitabine—kidney cancer	6.13e-05	0.00185	CcSEcCtD
Ruxolitinib—Infestation NOS—Capecitabine—kidney cancer	6.04e-05	0.00182	CcSEcCtD
Ruxolitinib—Infestation—Capecitabine—kidney cancer	6.04e-05	0.00182	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Sunitinib—kidney cancer	6.03e-05	0.00182	CcSEcCtD
Ruxolitinib—Asthenia—Vinblastine—kidney cancer	6.02e-05	0.00182	CcSEcCtD
Ruxolitinib—Fatigue—Sunitinib—kidney cancer	6.02e-05	0.00182	CcSEcCtD
Ruxolitinib—Asthenia—Everolimus—kidney cancer	6e-05	0.00181	CcSEcCtD
Ruxolitinib—Pruritus—Everolimus—kidney cancer	5.92e-05	0.00179	CcSEcCtD
Ruxolitinib—Infection—Vincristine—kidney cancer	5.87e-05	0.00177	CcSEcCtD
Ruxolitinib—Urinary tract infection—Capecitabine—kidney cancer	5.87e-05	0.00177	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Gemcitabine—kidney cancer	5.81e-05	0.00175	CcSEcCtD
Ruxolitinib—Nervous system disorder—Vincristine—kidney cancer	5.8e-05	0.00175	CcSEcCtD
Ruxolitinib—Asthenia—Erlotinib—kidney cancer	5.79e-05	0.00175	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Vincristine—kidney cancer	5.79e-05	0.00175	CcSEcCtD
Ruxolitinib—Haematuria—Capecitabine—kidney cancer	5.76e-05	0.00174	CcSEcCtD
Ruxolitinib—Malnutrition—Paclitaxel—kidney cancer	5.75e-05	0.00174	CcSEcCtD
Ruxolitinib—Body temperature increased—Sorafenib—kidney cancer	5.74e-05	0.00173	CcSEcCtD
Ruxolitinib—Hepatobiliary disease—Capecitabine—kidney cancer	5.71e-05	0.00172	CcSEcCtD
Ruxolitinib—Pruritus—Erlotinib—kidney cancer	5.71e-05	0.00172	CcSEcCtD
Ruxolitinib—Fatigue—Dactinomycin—kidney cancer	5.7e-05	0.00172	CcSEcCtD
Ruxolitinib—Epistaxis—Capecitabine—kidney cancer	5.7e-05	0.00172	CcSEcCtD
Ruxolitinib—Flatulence—Paclitaxel—kidney cancer	5.67e-05	0.00171	CcSEcCtD
Ruxolitinib—Infection—Gemcitabine—kidney cancer	5.57e-05	0.00168	CcSEcCtD
Ruxolitinib—Dizziness—Vinblastine—kidney cancer	5.55e-05	0.00168	CcSEcCtD
Ruxolitinib—Dizziness—Everolimus—kidney cancer	5.53e-05	0.00167	CcSEcCtD
Ruxolitinib—Body temperature increased—Sunitinib—kidney cancer	5.52e-05	0.00167	CcSEcCtD
Ruxolitinib—Nervous system disorder—Gemcitabine—kidney cancer	5.5e-05	0.00166	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Gemcitabine—kidney cancer	5.49e-05	0.00166	CcSEcCtD
Ruxolitinib—Haemoglobin—Capecitabine—kidney cancer	5.45e-05	0.00165	CcSEcCtD
Ruxolitinib—Skin disorder—Gemcitabine—kidney cancer	5.45e-05	0.00164	CcSEcCtD
Ruxolitinib—Haemorrhage—Capecitabine—kidney cancer	5.42e-05	0.00164	CcSEcCtD
Ruxolitinib—CYP3A4—renal system—kidney cancer	5.41e-05	0.00236	CbGeAlD
Ruxolitinib—Dizziness—Erlotinib—kidney cancer	5.34e-05	0.00161	CcSEcCtD
Ruxolitinib—Anaemia—Paclitaxel—kidney cancer	5.32e-05	0.0016	CcSEcCtD
Ruxolitinib—Headache—Vinblastine—kidney cancer	5.26e-05	0.00159	CcSEcCtD
Ruxolitinib—Headache—Everolimus—kidney cancer	5.24e-05	0.00158	CcSEcCtD
Ruxolitinib—CYP3A4—kidney—kidney cancer	5.23e-05	0.00228	CbGeAlD
Ruxolitinib—Body temperature increased—Dactinomycin—kidney cancer	5.23e-05	0.00158	CcSEcCtD
Ruxolitinib—Asthenia—Sorafenib—kidney cancer	5.21e-05	0.00157	CcSEcCtD
Ruxolitinib—Pruritus—Sorafenib—kidney cancer	5.14e-05	0.00155	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Vincristine—kidney cancer	5.1e-05	0.00154	CcSEcCtD
Ruxolitinib—Fatigue—Vincristine—kidney cancer	5.09e-05	0.00154	CcSEcCtD
Ruxolitinib—Headache—Erlotinib—kidney cancer	5.06e-05	0.00153	CcSEcCtD
Ruxolitinib—Gastrointestinal haemorrhage—Doxorubicin—kidney cancer	5.05e-05	0.00153	CcSEcCtD
Ruxolitinib—Asthenia—Sunitinib—kidney cancer	5.01e-05	0.00151	CcSEcCtD
Ruxolitinib—Pruritus—Sunitinib—kidney cancer	4.94e-05	0.00149	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—kidney cancer	4.86e-05	0.00147	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Gemcitabine—kidney cancer	4.84e-05	0.00146	CcSEcCtD
Ruxolitinib—Fatigue—Gemcitabine—kidney cancer	4.83e-05	0.00146	CcSEcCtD
Ruxolitinib—Dizziness—Sorafenib—kidney cancer	4.8e-05	0.00145	CcSEcCtD
Ruxolitinib—Asthenia—Dactinomycin—kidney cancer	4.75e-05	0.00143	CcSEcCtD
Ruxolitinib—Malnutrition—Capecitabine—kidney cancer	4.72e-05	0.00142	CcSEcCtD
Ruxolitinib—Body temperature increased—Vincristine—kidney cancer	4.67e-05	0.00141	CcSEcCtD
Ruxolitinib—Infection—Paclitaxel—kidney cancer	4.66e-05	0.00141	CcSEcCtD
Ruxolitinib—Flatulence—Capecitabine—kidney cancer	4.65e-05	0.0014	CcSEcCtD
Ruxolitinib—Dizziness—Sunitinib—kidney cancer	4.62e-05	0.00139	CcSEcCtD
Ruxolitinib—Nervous system disorder—Paclitaxel—kidney cancer	4.6e-05	0.00139	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Paclitaxel—kidney cancer	4.6e-05	0.00139	CcSEcCtD
Ruxolitinib—Skin disorder—Paclitaxel—kidney cancer	4.56e-05	0.00138	CcSEcCtD
Ruxolitinib—Headache—Sorafenib—kidney cancer	4.55e-05	0.00137	CcSEcCtD
Ruxolitinib—Alanine aminotransferase increased—Doxorubicin—kidney cancer	4.46e-05	0.00135	CcSEcCtD
Ruxolitinib—Body temperature increased—Gemcitabine—kidney cancer	4.43e-05	0.00134	CcSEcCtD
Ruxolitinib—Headache—Sunitinib—kidney cancer	4.38e-05	0.00132	CcSEcCtD
Ruxolitinib—Anaemia—Capecitabine—kidney cancer	4.36e-05	0.00132	CcSEcCtD
Ruxolitinib—Asthenia—Vincristine—kidney cancer	4.24e-05	0.00128	CcSEcCtD
Ruxolitinib—Pancytopenia—Doxorubicin—kidney cancer	4.15e-05	0.00125	CcSEcCtD
Ruxolitinib—Neutropenia—Doxorubicin—kidney cancer	4.08e-05	0.00123	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Paclitaxel—kidney cancer	4.05e-05	0.00122	CcSEcCtD
Ruxolitinib—Fatigue—Paclitaxel—kidney cancer	4.05e-05	0.00122	CcSEcCtD
Ruxolitinib—Asthenia—Gemcitabine—kidney cancer	4.02e-05	0.00121	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—kidney cancer	3.99e-05	0.0012	CcSEcCtD
Ruxolitinib—Weight increased—Doxorubicin—kidney cancer	3.97e-05	0.0012	CcSEcCtD
Ruxolitinib—Pruritus—Gemcitabine—kidney cancer	3.97e-05	0.0012	CcSEcCtD
Ruxolitinib—Weight decreased—Doxorubicin—kidney cancer	3.95e-05	0.00119	CcSEcCtD
Ruxolitinib—Dizziness—Vincristine—kidney cancer	3.91e-05	0.00118	CcSEcCtD
Ruxolitinib—Infestation—Doxorubicin—kidney cancer	3.89e-05	0.00118	CcSEcCtD
Ruxolitinib—Infestation NOS—Doxorubicin—kidney cancer	3.89e-05	0.00118	CcSEcCtD
Ruxolitinib—Infection—Capecitabine—kidney cancer	3.83e-05	0.00116	CcSEcCtD
Ruxolitinib—Urinary tract infection—Doxorubicin—kidney cancer	3.78e-05	0.00114	CcSEcCtD
Ruxolitinib—Nervous system disorder—Capecitabine—kidney cancer	3.78e-05	0.00114	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Capecitabine—kidney cancer	3.77e-05	0.00114	CcSEcCtD
Ruxolitinib—Skin disorder—Capecitabine—kidney cancer	3.74e-05	0.00113	CcSEcCtD
Ruxolitinib—Haematuria—Doxorubicin—kidney cancer	3.71e-05	0.00112	CcSEcCtD
Ruxolitinib—Body temperature increased—Paclitaxel—kidney cancer	3.71e-05	0.00112	CcSEcCtD
Ruxolitinib—Headache—Vincristine—kidney cancer	3.7e-05	0.00112	CcSEcCtD
Ruxolitinib—Hepatobiliary disease—Doxorubicin—kidney cancer	3.68e-05	0.00111	CcSEcCtD
Ruxolitinib—Epistaxis—Doxorubicin—kidney cancer	3.67e-05	0.00111	CcSEcCtD
Ruxolitinib—DYRK1A—Idarubicin—Doxorubicin—kidney cancer	3.63e-05	0.0308	CbGdCrCtD
Ruxolitinib—DYRK1A—Epirubicin—Doxorubicin—kidney cancer	3.63e-05	0.0308	CbGdCrCtD
Ruxolitinib—DYRK1A—Daunorubicin—Doxorubicin—kidney cancer	3.63e-05	0.0308	CbGdCrCtD
Ruxolitinib—Haemoglobin—Doxorubicin—kidney cancer	3.51e-05	0.00106	CcSEcCtD
Ruxolitinib—Headache—Gemcitabine—kidney cancer	3.51e-05	0.00106	CcSEcCtD
Ruxolitinib—Haemorrhage—Doxorubicin—kidney cancer	3.49e-05	0.00106	CcSEcCtD
Ruxolitinib—Asthenia—Paclitaxel—kidney cancer	3.37e-05	0.00102	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Capecitabine—kidney cancer	3.33e-05	0.001	CcSEcCtD
Ruxolitinib—Fatigue—Capecitabine—kidney cancer	3.32e-05	0.001	CcSEcCtD
Ruxolitinib—Pruritus—Paclitaxel—kidney cancer	3.32e-05	0.001	CcSEcCtD
Ruxolitinib—Dizziness—Paclitaxel—kidney cancer	3.1e-05	0.000937	CcSEcCtD
Ruxolitinib—Body temperature increased—Capecitabine—kidney cancer	3.04e-05	0.000919	CcSEcCtD
Ruxolitinib—Malnutrition—Doxorubicin—kidney cancer	3.04e-05	0.000919	CcSEcCtD
Ruxolitinib—Flatulence—Doxorubicin—kidney cancer	3e-05	0.000905	CcSEcCtD
Ruxolitinib—Headache—Paclitaxel—kidney cancer	2.94e-05	0.000888	CcSEcCtD
Ruxolitinib—PLK1—Cytarabine—Gemcitabine—kidney cancer	2.89e-05	0.0245	CbGdCrCtD
Ruxolitinib—Anaemia—Doxorubicin—kidney cancer	2.81e-05	0.000849	CcSEcCtD
Ruxolitinib—Asthenia—Capecitabine—kidney cancer	2.76e-05	0.000834	CcSEcCtD
Ruxolitinib—Pruritus—Capecitabine—kidney cancer	2.73e-05	0.000823	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—kidney cancer	2.57e-05	0.000777	CcSEcCtD
Ruxolitinib—Dizziness—Capecitabine—kidney cancer	2.55e-05	0.000769	CcSEcCtD
Ruxolitinib—PLK1—Idarubicin—Doxorubicin—kidney cancer	2.48e-05	0.021	CbGdCrCtD
Ruxolitinib—PLK4—Epirubicin—Doxorubicin—kidney cancer	2.48e-05	0.021	CbGdCrCtD
Ruxolitinib—PLK1—Epirubicin—Doxorubicin—kidney cancer	2.48e-05	0.021	CbGdCrCtD
Ruxolitinib—PLK4—Idarubicin—Doxorubicin—kidney cancer	2.48e-05	0.021	CbGdCrCtD
Ruxolitinib—PLK1—Daunorubicin—Doxorubicin—kidney cancer	2.48e-05	0.021	CbGdCrCtD
Ruxolitinib—Infection—Doxorubicin—kidney cancer	2.47e-05	0.000745	CcSEcCtD
Ruxolitinib—Nervous system disorder—Doxorubicin—kidney cancer	2.43e-05	0.000735	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Doxorubicin—kidney cancer	2.43e-05	0.000734	CcSEcCtD
Ruxolitinib—Headache—Capecitabine—kidney cancer	2.41e-05	0.000729	CcSEcCtD
Ruxolitinib—Skin disorder—Doxorubicin—kidney cancer	2.41e-05	0.000728	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Doxorubicin—kidney cancer	2.14e-05	0.000647	CcSEcCtD
Ruxolitinib—Fatigue—Doxorubicin—kidney cancer	2.14e-05	0.000646	CcSEcCtD
Ruxolitinib—Body temperature increased—Doxorubicin—kidney cancer	1.96e-05	0.000593	CcSEcCtD
Ruxolitinib—Asthenia—Doxorubicin—kidney cancer	1.78e-05	0.000538	CcSEcCtD
Ruxolitinib—Pruritus—Doxorubicin—kidney cancer	1.76e-05	0.00053	CcSEcCtD
Ruxolitinib—Dizziness—Doxorubicin—kidney cancer	1.64e-05	0.000496	CcSEcCtD
Ruxolitinib—Headache—Doxorubicin—kidney cancer	1.56e-05	0.00047	CcSEcCtD
Ruxolitinib—JAK3—Signaling Pathways—CCND1—kidney cancer	6.78e-07	1.33e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—CDH1—kidney cancer	6.77e-07	1.33e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—CDKN1B—kidney cancer	6.77e-07	1.33e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—JUN—kidney cancer	6.76e-07	1.33e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—CDKN2B—kidney cancer	6.75e-07	1.33e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling by GPCR—PIK3CA—kidney cancer	6.72e-07	1.32e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—CTNNB1—kidney cancer	6.71e-07	1.32e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—KRAS—kidney cancer	6.68e-07	1.31e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—MYC—kidney cancer	6.68e-07	1.31e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—RAF1—kidney cancer	6.67e-07	1.31e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—JUN—kidney cancer	6.64e-07	1.3e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—RELA—kidney cancer	6.64e-07	1.3e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—IL2—kidney cancer	6.62e-07	1.3e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—MAPK3—kidney cancer	6.62e-07	1.3e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—PTEN—kidney cancer	6.62e-07	1.3e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling by GPCR—PIK3CA—kidney cancer	6.61e-07	1.3e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—KDR—kidney cancer	6.61e-07	1.3e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—ERBB2—kidney cancer	6.6e-07	1.3e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—CTNNB1—kidney cancer	6.59e-07	1.29e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—RAF1—kidney cancer	6.56e-07	1.29e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—IGF1R—kidney cancer	6.56e-07	1.29e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Hemostasis—PIK3CA—kidney cancer	6.55e-07	1.29e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—PTEN—kidney cancer	6.54e-07	1.28e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—MAPK1—kidney cancer	6.53e-07	1.28e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—RELA—kidney cancer	6.53e-07	1.28e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—MTOR—kidney cancer	6.51e-07	1.28e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—ERBB2—kidney cancer	6.49e-07	1.27e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—KIT—kidney cancer	6.46e-07	1.27e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—APC—kidney cancer	6.46e-07	1.27e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—JUN—kidney cancer	6.44e-07	1.26e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—CDKN1B—kidney cancer	6.44e-07	1.26e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—MYC—kidney cancer	6.44e-07	1.26e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—PTEN—kidney cancer	6.43e-07	1.26e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—KRAS—kidney cancer	6.42e-07	1.26e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—MTOR—kidney cancer	6.41e-07	1.26e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—GPC3—kidney cancer	6.39e-07	1.26e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—CTNNB1—kidney cancer	6.39e-07	1.26e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—BRAF—kidney cancer	6.38e-07	1.25e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Hemostasis—TP53—kidney cancer	6.34e-07	1.24e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—RAF1—kidney cancer	6.32e-07	1.24e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—MAPK1—kidney cancer	6.3e-07	1.24e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—APC—kidney cancer	6.27e-07	1.23e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—KIT—kidney cancer	6.27e-07	1.23e-05	CbGpPWpGaD
Ruxolitinib—JAK2—GPCR downstream signaling—IL2—kidney cancer	6.24e-07	1.22e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—PTEN—kidney cancer	6.23e-07	1.22e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—CA2—kidney cancer	6.22e-07	1.22e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—KRAS—kidney cancer	6.17e-07	1.21e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—POMC—kidney cancer	6.15e-07	1.21e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—PIK3CA—kidney cancer	6.14e-07	1.21e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—CDKN1B—kidney cancer	6.11e-07	1.2e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—CTNNB1—kidney cancer	6.09e-07	1.19e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—APC—kidney cancer	6.09e-07	1.19e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—KIT—kidney cancer	6.09e-07	1.19e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—BRAF—kidney cancer	6.07e-07	1.19e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—ALAD—kidney cancer	6.06e-07	1.19e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—CDKN1B—kidney cancer	6.01e-07	1.18e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—MAPK3—kidney cancer	6.01e-07	1.18e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—IL2—kidney cancer	5.98e-07	1.17e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—POMC—kidney cancer	5.97e-07	1.17e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—KRAS—kidney cancer	5.95e-07	1.17e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—PTEN—kidney cancer	5.93e-07	1.16e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—ST3GAL2—kidney cancer	5.92e-07	1.16e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—VEGFA—kidney cancer	5.91e-07	1.16e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—PIK3CA—kidney cancer	5.9e-07	1.16e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—BRAF—kidney cancer	5.9e-07	1.16e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—IL2—kidney cancer	5.88e-07	1.15e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—CCND1—kidney cancer	5.83e-07	1.14e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—JUN—kidney cancer	5.82e-07	1.14e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—POMC—kidney cancer	5.79e-07	1.14e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—ALDH1A1—kidney cancer	5.78e-07	1.14e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—CTNNB1—kidney cancer	5.77e-07	1.13e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—RAF1—kidney cancer	5.77e-07	1.13e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—RELA—kidney cancer	5.75e-07	1.13e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—CCND1—kidney cancer	5.73e-07	1.13e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—JUN—kidney cancer	5.72e-07	1.12e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—BRAF—kidney cancer	5.72e-07	1.12e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—MAPK1—kidney cancer	5.72e-07	1.12e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—ERBB2—kidney cancer	5.71e-07	1.12e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—CTNNB1—kidney cancer	5.68e-07	1.11e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—PIK3CA—kidney cancer	5.67e-07	1.11e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—IL2—kidney cancer	5.66e-07	1.11e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—MAPK3—kidney cancer	5.66e-07	1.11e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—MTOR—kidney cancer	5.64e-07	1.11e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—PTEN—kidney cancer	5.63e-07	1.1e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—CD4—kidney cancer	5.62e-07	1.1e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—MAPK3—kidney cancer	5.59e-07	1.1e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PGK1—kidney cancer	5.54e-07	1.09e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—SLC5A3—kidney cancer	5.54e-07	1.09e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—PTEN—kidney cancer	5.53e-07	1.09e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—MAPK3—kidney cancer	5.49e-07	1.08e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—PIK3CA—kidney cancer	5.47e-07	1.07e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—LDHB—kidney cancer	5.44e-07	1.07e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—MYC—kidney cancer	5.44e-07	1.07e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—KRAS—kidney cancer	5.4e-07	1.06e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—HIF1A—kidney cancer	5.4e-07	1.06e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—TSC2—kidney cancer	5.38e-07	1.06e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—MAPK1—kidney cancer	5.38e-07	1.06e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—RAF1—kidney cancer	5.33e-07	1.05e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—MAPK3—kidney cancer	5.32e-07	1.05e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—MAPK1—kidney cancer	5.32e-07	1.04e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—TP53—kidney cancer	5.29e-07	1.04e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—CDKN1B—kidney cancer	5.29e-07	1.04e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—ERBB2—kidney cancer	5.27e-07	1.04e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—MAPK1—kidney cancer	5.22e-07	1.03e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—MTOR—kidney cancer	5.2e-07	1.02e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—CD4—kidney cancer	5.19e-07	1.02e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—IL2—kidney cancer	5.18e-07	1.02e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—KDR—kidney cancer	5.16e-07	1.01e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—PTGS2—kidney cancer	5.16e-07	1.01e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—VEGFA—kidney cancer	5.08e-07	9.98e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—KRAS—kidney cancer	5.08e-07	9.98e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—RAF1—kidney cancer	5.07e-07	9.96e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—MAPK3—kidney cancer	5.07e-07	9.95e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—MAPK1—kidney cancer	5.07e-07	9.95e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—RELA—kidney cancer	5.05e-07	9.91e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—JUN—kidney cancer	5.03e-07	9.88e-06	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—KRAS—kidney cancer	5.02e-07	9.86e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—ERBB2—kidney cancer	5.02e-07	9.85e-06	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—VEGFA—kidney cancer	5e-07	9.81e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—CTNNB1—kidney cancer	5e-07	9.81e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—PIK3CA—kidney cancer	4.96e-07	9.74e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—MTOR—kidney cancer	4.95e-07	9.72e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—KRAS—kidney cancer	4.93e-07	9.69e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—MYC—kidney cancer	4.93e-07	9.68e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—RAF1—kidney cancer	4.92e-07	9.67e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—RELA—kidney cancer	4.9e-07	9.62e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—CDKN1B—kidney cancer	4.88e-07	9.59e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—ERBB2—kidney cancer	4.87e-07	9.56e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—PTEN—kidney cancer	4.87e-07	9.56e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—MAPK1—kidney cancer	4.82e-07	9.47e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—MAPK3—kidney cancer	4.81e-07	9.44e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—MTOR—kidney cancer	4.81e-07	9.44e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—KRAS—kidney cancer	4.79e-07	9.39e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—RAF1—kidney cancer	4.78e-07	9.38e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—KIT—kidney cancer	4.75e-07	9.33e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—APC—kidney cancer	4.75e-07	9.33e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—RELA—kidney cancer	4.75e-07	9.33e-06	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—MAPK3—kidney cancer	4.73e-07	9.28e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—ERBB2—kidney cancer	4.73e-07	9.28e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—CA9—kidney cancer	4.71e-07	9.25e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—MYC—kidney cancer	4.68e-07	9.18e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—PIK3CA—kidney cancer	4.67e-07	9.17e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—MTOR—kidney cancer	4.66e-07	9.15e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—CDKN1B—kidney cancer	4.65e-07	9.12e-06	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—PIK3CA—kidney cancer	4.61e-07	9.06e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—CTNNB1—kidney cancer	4.61e-07	9.06e-06	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—MYC—kidney cancer	4.6e-07	9.03e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—MAPK1—kidney cancer	4.58e-07	8.98e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—KRAS—kidney cancer	4.56e-07	8.94e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—MAPK3—kidney cancer	4.55e-07	8.94e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—IL2—kidney cancer	4.55e-07	8.93e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—PIK3CA—kidney cancer	4.53e-07	8.9e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—POMC—kidney cancer	4.53e-07	8.89e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—CDKN1B—kidney cancer	4.51e-07	8.86e-06	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—MAPK1—kidney cancer	4.5e-07	8.83e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—PTEN—kidney cancer	4.5e-07	8.83e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—BRAF—kidney cancer	4.47e-07	8.77e-06	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—TP53—kidney cancer	4.46e-07	8.76e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—CCND1—kidney cancer	4.43e-07	8.7e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—JUN—kidney cancer	4.42e-07	8.69e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—IL2—kidney cancer	4.42e-07	8.67e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—PIK3CA—kidney cancer	4.4e-07	8.63e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—CTNNB1—kidney cancer	4.39e-07	8.62e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—CDKN1B—kidney cancer	4.38e-07	8.59e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—MAPK1—kidney cancer	4.33e-07	8.51e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—KRAS—kidney cancer	4.32e-07	8.48e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—CCND1—kidney cancer	4.3e-07	8.45e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—JUN—kidney cancer	4.3e-07	8.43e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—IL2—kidney cancer	4.28e-07	8.41e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—PTEN—kidney cancer	4.28e-07	8.4e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—CTNNB1—kidney cancer	4.26e-07	8.37e-06	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—KRAS—kidney cancer	4.25e-07	8.34e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—PIK3CA—kidney cancer	4.19e-07	8.22e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—CCND1—kidney cancer	4.17e-07	8.2e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—JUN—kidney cancer	4.17e-07	8.18e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—MAPK3—kidney cancer	4.16e-07	8.17e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—PTEN—kidney cancer	4.15e-07	8.16e-06	CbGpPWpGaD
Ruxolitinib—JAK2—GPCR downstream signaling—PIK3CA—kidney cancer	4.14e-07	8.13e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—CTNNB1—kidney cancer	4.13e-07	8.12e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—KRAS—kidney cancer	4.09e-07	8.03e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—PTEN—kidney cancer	4.03e-07	7.91e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—CRABP1—kidney cancer	4.01e-07	7.87e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—PIK3CA—kidney cancer	3.97e-07	7.79e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—MAPK1—kidney cancer	3.96e-07	7.77e-06	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—PIK3CA—kidney cancer	3.9e-07	7.67e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—VEGFA—kidney cancer	3.87e-07	7.59e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—MAPK3—kidney cancer	3.84e-07	7.54e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—TP53—kidney cancer	3.84e-07	7.54e-06	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—TP53—kidney cancer	3.78e-07	7.42e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—PIK3CA—kidney cancer	3.76e-07	7.38e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—VEGFA—kidney cancer	3.75e-07	7.37e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—KRAS—kidney cancer	3.74e-07	7.34e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—MYC—kidney cancer	3.74e-07	7.33e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—RAF1—kidney cancer	3.73e-07	7.33e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—ITPR2—kidney cancer	3.73e-07	7.32e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—RELA—kidney cancer	3.72e-07	7.29e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—ERBB2—kidney cancer	3.69e-07	7.25e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—MAPK3—kidney cancer	3.66e-07	7.18e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—MAPK1—kidney cancer	3.66e-07	7.18e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—MTOR—kidney cancer	3.64e-07	7.15e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—VEGFA—kidney cancer	3.64e-07	7.14e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—MYC—kidney cancer	3.56e-07	6.98e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—MAPK3—kidney cancer	3.55e-07	6.97e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—MAPK1—kidney cancer	3.48e-07	6.83e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—MYC—kidney cancer	3.45e-07	6.78e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—KRAS—kidney cancer	3.45e-07	6.78e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—MAPK3—kidney cancer	3.44e-07	6.76e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—PIK3CA—kidney cancer	3.44e-07	6.74e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—CDKN1B—kidney cancer	3.42e-07	6.71e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—GSTT1—kidney cancer	3.4e-07	6.67e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—ACHE—kidney cancer	3.4e-07	6.67e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—MAPK1—kidney cancer	3.38e-07	6.63e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—MYC—kidney cancer	3.35e-07	6.57e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—IL2—kidney cancer	3.35e-07	6.57e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—KRAS—kidney cancer	3.29e-07	6.45e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—MAPK1—kidney cancer	3.28e-07	6.43e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—CCND1—kidney cancer	3.26e-07	6.4e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—JUN—kidney cancer	3.26e-07	6.39e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—CTNNB1—kidney cancer	3.23e-07	6.34e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—SCARB1—kidney cancer	3.22e-07	6.31e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—KRAS—kidney cancer	3.19e-07	6.26e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PTGS1—kidney cancer	3.18e-07	6.25e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—PIK3CA—kidney cancer	3.17e-07	6.23e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—PTEN—kidney cancer	3.15e-07	6.18e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PSMD7—kidney cancer	3.12e-07	6.13e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—KRAS—kidney cancer	3.09e-07	6.07e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—PIK3CA—kidney cancer	3.02e-07	5.93e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—BCHE—kidney cancer	2.96e-07	5.81e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—PIK3CA—kidney cancer	2.93e-07	5.75e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—SLC5A5—kidney cancer	2.92e-07	5.74e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—TP53—kidney cancer	2.92e-07	5.73e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—VEGFA—kidney cancer	2.84e-07	5.58e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—PIK3CA—kidney cancer	2.84e-07	5.58e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—TP53—kidney cancer	2.84e-07	5.57e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—SLC2A1—kidney cancer	2.82e-07	5.54e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—TP53—kidney cancer	2.75e-07	5.4e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—MAPK3—kidney cancer	2.69e-07	5.28e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—MYC—kidney cancer	2.62e-07	5.14e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—MAPK1—kidney cancer	2.56e-07	5.02e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—KRAS—kidney cancer	2.42e-07	4.75e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—GSTP1—kidney cancer	2.36e-07	4.62e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—ABCB1—kidney cancer	2.23e-07	4.38e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—PIK3CA—kidney cancer	2.22e-07	4.36e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—GSTM1—kidney cancer	2.16e-07	4.25e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—TP53—kidney cancer	2.15e-07	4.22e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—CYP1A1—kidney cancer	2.05e-07	4.03e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—POMC—kidney cancer	1.53e-07	3e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PTGS2—kidney cancer	1.22e-07	2.4e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PTEN—kidney cancer	1.06e-07	2.09e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PIK3CA—kidney cancer	7.51e-08	1.47e-06	CbGpPWpGaD
